CuraTeQ Biologics s.r.o

Company snapshot

𝗖𝘂𝗿𝗮𝗧𝗲𝗤 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 (a wholly owned subsidiary of Aurobindo Pharma Ltd.) is an 𝗘𝗨 𝗚𝗠𝗣 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 biopharmaceutical company headquartered in Hyderabad, India. Our vision is to improve the wellbeing of patients suffering from debilitating illnesses by providing them access to high quality and cost-effective biosimilars. CuraTeQ has a development pipeline of 14 biosimilars,

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CuraTeQ Biologics s.r.o. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CuraTeQ Biologics s.r.o.

1. Jun 8, 2026 Clinical update

   CR213-20 — Phase 3

2. Jun 8, 2026 Clinical update

   BP11-301 — Phase 3

View all clinical trial activity →

• What is CuraTeQ Biologics s.r.o?

  CuraTeQ Biologics is a pharma organization headquartered in Hyderabad, IN. Primary therapeutic focus areas include wet macula degeneration, Chronic Urticaria. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA

• Is CuraTeQ Biologics s.r.o publicly traded?

  CuraTeQ Biologics s.r.o appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does CuraTeQ Biologics s.r.o develop or market?

  We link 6 drug profile(s) where CuraTeQ Biologics s.r.o is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/curateq-biologics-s-r-o#company-drugs.

• What are the latest developments for CuraTeQ Biologics s.r.o?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CuraTeQ Biologics s.r.o focus on?

  CuraTeQ Biologics s.r.o focuses on wet macula degeneration, Chronic Urticaria based on our analysis of their pipeline programs and drug development activities.